Tags: blood cancerbortezomibcancerdexamethasonehematologylenalidomidelong term survival outcomesmedian progression free survivalmelflufenmelphalan flufenamidemulticentremultiple myelomaneutropeniaoncologyopen labelopen label trialoverall survivalprogression-free survivalrelapsed and refractory multiple myelomaRRMMsafetysurvival outcomesthrombocytopenia
Want more physician-written
medical news?
Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.
Subscribe for free today!